2015
DOI: 10.1016/bs.adgen.2014.10.005
|View full text |Cite
|
Sign up to set email alerts
|

Self-Amplifying mRNA Vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
176
0
3

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 153 publications
(179 citation statements)
references
References 201 publications
(258 reference statements)
0
176
0
3
Order By: Relevance
“…Unlike protein immunization, several formats of mRNA vaccines induce strong CD8 + T cell responses, likely owing to the efficient presentation of endogenously produced antigens on MHC class I molecules, in addition to potent CD4 + T cell responses 56,87,88 . Additionally, unlike DNA immunization, mRNA vaccines have shown the ability to generate potent neutralizing antibody responses in animals with only one or two low-dose immunizations 20,22,85 .…”
Section: Mrna Vaccines Against Infectious Diseasesmentioning
confidence: 99%
See 1 more Smart Citation
“…Unlike protein immunization, several formats of mRNA vaccines induce strong CD8 + T cell responses, likely owing to the efficient presentation of endogenously produced antigens on MHC class I molecules, in addition to potent CD4 + T cell responses 56,87,88 . Additionally, unlike DNA immunization, mRNA vaccines have shown the ability to generate potent neutralizing antibody responses in animals with only one or two low-dose immunizations 20,22,85 .…”
Section: Mrna Vaccines Against Infectious Diseasesmentioning
confidence: 99%
“…SAM vaccines encoding influenza virus antigens in LNPs or an oil-in-water cationic nanoemulsion induced potent immune responses in ferrets and conferred protection from homologous and heterologous viral challenge in mice 9496 . Further studies demonstrated the immunogenicity of this vaccine platform against diverse viruses in multiple species, including human cytomegalovirus (CMV), hepatitis C virus and rabies virus in mice, HIV-1 in rabbits, and HIV-1 and human CMV in rhesus macaques 50,87,97 . Replicon RNA encoding influenza antigens, complexed with chitosan-containing LNPs or polyethylenimine (PEI), has elicited T and B cell immune responses in mice after subcutaneous delivery 98,99 .…”
Section: Mrna Vaccines Against Infectious Diseasesmentioning
confidence: 99%
“…In 2012, Geall et al (2012) used a combination of the following components: 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), DSPC, cholesterol, and PEG2k-DMG to deliver self-amplifying RNA (saRNA, also termed as self-amplifying mRNA, SAM) as therapeutic vaccines. The commonly used saRNA is derived from alphavirus genome, which retains the alphavirus genes encoding replication components and replaces the structural protein genes with those encoding antigens of interest (Bogers et al, 2014;Brito et al, 2015;Ljungberg & Liljeström, 2014;Midoux & Pichon, 2015;Ulmer & Geall, 2016). After intramuscular injection, the lipid nanoparticles (LNP/saRNA) induced Respiratory Syncytial Virus Fusion Glycoprotien-specific antibody and T-cell responses in both mice and rats (Geall et al, 2012).…”
Section: Lipid and Lipid-derived Nanoparticles For Mrna Deliverymentioning
confidence: 99%
“…mRNA vaccines are another promising alternative to conventional vaccine approaches because they comprise a non‐infectious, rapid, cost‐effective and non‐integrating platform with high potency . Moreover, mRNA can induce protein expression without crossing the nuclear barrier.…”
Section: Cancer Immunotherapy By Regulating Dendritic Cells With Non‐mentioning
confidence: 99%